Acetyl tetrapeptide-5
is used in cosmetic eye formulations to decrease puffiness, eye bags, and dark circles by reducing edema and protecting proteins such as SOD from glycation
Alanine
Ala / A · hydrophobic residue · neutral charge
AOD-9604
is studied as an anti-obesity peptide that can reduce weight gain and increase fat oxidation in obese animal models with generally neutral effects on IGF-1 and glucose metabolism in early human trials
Arginine
Arg / R · basic residue · positive charge
Argireline
is a topical cosmetic peptide reported to decrease dynamic wrinkles by partially mimicking the mechanism of botulinum toxin in a non-invasive manner
Asparagine
Asn / N · polar residue · neutral charge
Aspartic acid
Asp / D · acidic residue · negative charge
BPC-157
is investigated for accelerating healing of gastrointestinal mucosa, tendons, ligaments, bone, and nervous tissue in preclinical models, with anti-inflammatory and pro-angiogenic effects
Comparison
While Liraglutide is approved for type 2 diabetes and weight management, improving glycemic control and inducing weight loss through GLP-1–mediated insulinotropic, glucagonostatic, and appetite-suppressing actions6880, MGF is upregulated in muscle after mechanical overload, where it supports tissue repair and growth; recombinant forms are studied for regenerative and performance-enhancement effects22138.
While Liraglutide works as a human GLP-1 analog with a single amino-acid substitution (Lys34→Arg) and a C16 palmitoyl fatty acid attached to Lys26 via a glutamate linker, producing a long-acting GLP-1 receptor agonist6880, MGF is a 24-amino-acid E-peptide splice variant of IGF-1 (IGF-1Ec) produced in mechanically stressed or damaged muscle that activates IGF1R and local anabolic pathways involved in muscle repair and hypertrophy22138144.
Liraglutide
GCG
MGF
IGF1
Liraglutide and MGF are noticeably different, with limited direct overlap in their usual biological context. Their typical research and application settings separate fairly clearly: Liraglutide is more often discussed in the realm of Metabolic and endocrine, whereas MGF is more often associated with the realm of Musculoskeletal health. Their biological logic is quite different: Liraglutide is a receptor agonist and a hormone analog, whereas MGF is a growth factor mimetic and a signaling modulator. Liraglutide has a more synthetic analog origin, while MGF is closer to natural endogenous background and their development context also differs, with Liraglutide approved while MGF is in Preclinical development. Liraglutide takes the form of a peptide conjugate, whereas MGF is closer to a linear peptide, Liraglutide incorporates palmitoylation features that are not part of MGF; while their sequence patterns also diverge, with Liraglutide showing alpha-helical domain features and MGF showing protein-mimetic sequence features.